Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: CANCER ; CELLS ; tumor ; BLOOD ; CELL ; Germany ; THERAPY ; TIME ; PATIENT ; TRANSPLANTATION ; treatment ; BONE-MARROW ; BREAST-CANCER ; TARGET ; chemotherapy ; EFFICIENT ; STEM-CELLS ; PROGENITOR CELLS ; CANCER-PATIENTS ; BODY ; CYCLOPHOSPHAMIDE ; CANCER PATIENTS ; PERIPHERAL-BLOOD ; MULTICENTER ; MULTIPLE-MYELOMA ; SINGLE ; HIGH-DOSE CHEMOTHERAPY ; multiple myeloma ; ONCOLOGY ; WEIGHT ; stem cells ; dexamethasone ; pegfilgrastim ; MOBILIZATION ; immunology ; STEM ; myeloma ; ADJUNCT ; ADMINISTRATION PEGFILGRASTIM ; apheresis ; DAILY FILGRASTIM ; peripheral blood stem cell ; PRETREATED LYMPHOMA PATIENTS ; REGIMEN ; STAGE-II
    Abstract: High-dose chemotherapy followed by autologous blood stem cell transplantation is the standard treatment for myeloma patients. In this study, CAD (cyclophosphamide, adriamycin, dexamethasone) chemotherapy and a single dose of peg. lgrastim (12 mg) was highly effective ve in mobilizing peripheral blood stem cells (PBSCs) for subsequent transplantation, with 88% of patients (n = 26) achieving the CD34(+) cell harvest target of 〉= 7.50 x 106 CD34(+) cells/ kg body weig ht, following a median of two apheresis procedures (range 1 -4) and with. rst apheresis performed at a median day 13 after CAD application (range 10 -20). Patients treated with peg. lgrastim showed a reduced time to. rst apheresis procedure from mobilization compared with. lgrastim-mobilized historical matched controls (n = 52, P = 0.015). The peg. lgrastim mobilization regimen allowed for transplantation of a median of 3.58 x 10 6 CD34(+) cells/ kg body weight while leaving suf. ficient stored cells for a second high-dose regimen and back-ups in most patients. Engraftment following transplantation was comparable to. lgrastim, with a median time of 14 days to leucocyte 〉= 1.0 x 109/l (range 10 -21) and 11 days to platelets 〉= 20 x 109/l (range 0 -15). The results of this study thus provide further support for the clinical utility of peg. lgrastim for the mobilization of PBSC following chemotherapy in cancer patients scheduled for transplantation
    Type of Publication: Journal article published
    PubMed ID: 17450182
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CELLS ; CELL ; Germany ; human ; THERAPY ; CLASSIFICATION ; SITE ; GENE ; GENOME ; TISSUE ; gene therapy ; MICE ; DNA ; TISSUES ; MR ; BONE-MARROW ; NOD/Scid mice ; ACID ; NUCLEIC-ACIDS ; IMMUNODEFICIENT MICE ; STEM-CELLS ; POLYMERASE-CHAIN-REACTION ; CD34(+) CELLS ; PERIPHERAL-BLOOD ; GENE-THERAPY ; HEMATOPOIETIC STEM-CELLS ; IMMUNE-DEFICIENT MICE ; clonality ; JUNCTIONS ; LIBRARIES ; BLOOD PROGENITOR CELLS ; experimental PBPC transplantation ; RESISTANCE 1 GENE ; SCID-repopulating cells ; single cell analysis ; TIME QUANTITATIVE PCR
    Abstract: Methods to analyze the clonality of an adverse event in preclinical or clinical retroviral stem cell gene therapy protocols are needed. We analyzed the progeny of retrovirally transduced human peripheral blood progenitor cells (PBPCs) after transplantation and engraftment in immune-deficient mice. The integration site of the provirus serves as a unique tag of the individual transduced PBPC. A plasmid library of junctions between proviral and human genomic DNA was generated. We were able to detect individual transduced cell clones that amounted to 0.14%-0.0001% of chimeric bone marrow cells. This is the first report in which the contribution of individual marrow-repopulating cells to human hematopoiesis is directly quantified
    Type of Publication: Journal article published
    PubMed ID: 15277702
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: CELLS ; EXPRESSION ; INHIBITOR ; BLOOD ; CELL ; Germany ; KINASE ; PATHWAY ; TYROSINE KINASE ; RNA ; transcription ; cell line ; LINES ; PATIENT ; MECHANISM ; FLOW ; CELL-LINES ; TYROSINE KINASE INHIBITOR ; MOLECULE ; bone marrow ; BONE-MARROW ; leukemia ; LINE ; TRAFFICKING ; ADHESION ; CELL-ADHESION ; PROGENITOR CELLS ; POLYMERASE-CHAIN-REACTION ; ADHESION MOLECULE ; CD34(+) CELLS ; CHRONIC MYELOGENOUS LEUKEMIA ; chronic myelogenous leukemia,adhesion molecule,L-selectin,imatinib mesylate ; CHRONIC MYELOID-LEUKEMIA ; CYTOGENETIC RESPONSES ; FLOW-CYTOMETRY ; HEMATOPOIETIC PROGENITOR CELLS ; HEMATOPOIETIC-CELLS ; imatinib ; INTERFERON-ALPHA RESTORES ; L-SELECTIN EXPRESSION ; MARROW STROMA ; PERIPHERAL-BLOOD
    Abstract: Chronic myelogenous leukemia (CML) is characterized by aberrant trafficking of malignant hematopoietic progenitor cells in the peripheral blood. Expression of the cell adhesion molecule CD62L was reported to be significantly lower in CML patients than in normal controls. We studied whether the transcription of CD62L in CML cells is dependent on the activity of the BCR-ABL tyrosine kinase. Following addition of the Abelson (ABL) tyrosine kinase inhibitor imatinib (formerly STI571) to two BCR-ABL-positive cell lines (BV173, SD-1), we observed a dose-dependent increase in CD62L RNA levels of up to 45-fold by a quantitative, real-time polymerase chain reaction and an increase in the amount of cell surface-bound CD62L of up to 18-fold by quantitative flow cytometry, respectively. These data are validated by an increased CD62L expression in the bone marrow of patients (n=6) with advanced CML who received imatinib. Restoration of defective cell adhesion mediated via the CD62L pathway may be one mechanism of action of imatinib in BCR-ABL-positive leukemias
    Type of Publication: Journal article published
    PubMed ID: 12714574
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...